In order to promote the use of multigene panel testing of breast cancer patients, we need to understand the prevalence of germline mutations particularly in cancer predisposition genes beyond BRCA1/2 to identify the genes commonly mutated in our population. This evidence concerns the gene BRCA1 and breast carcinoma.